Pharma business info

The pharmaceutical business has lifted up fears over parts of US President US President Barack Obama’s fiscal 2013 financial plan, claiming that the proposals could resulted in considerable job losses in the division.

Drug maufacturer GlaxoSmithKline Pharmaceuticals stated that the continued expansion of specialty products and vaccines, novel product launches and taut expense control assisted perk up profits.

Scrip of Sun Pharmaceutical Industries on Feb 16 declined around 3%, as the company stated that that US-based Wyeth Pharmaceuticals has sought compensation worth $960 million in a patent clash.

DARA BioSciences has entered into an exclusive United States deal with Uman Pharma for commercial rights to gemcitabine, an anticancer agent.

Aurobindo Pharma Ltd’s scrip dropped 5.67% on the Bombay Stock Exchange (BSE) on February 10 following reports of IT raids and sudden annulment of board conference.

Cambridge based Ironwood Pharmaceuticals has declared that it is offering up 5.3 million Class A scrips to aid toughen its balance sheet.

The ex biz development director of Takeda Pharmaceuticals International made $63,000 in profits from insider trading.

Sun Pharmaceuticals, India’s biggest drug manufacturer by market cap, is ready to declare its outcomes for the three month period ended December FY12 on February 13.

The FDA has given sanction to the topical ivermectin 0.5% ointment (Sklice) for the cure of head lice in sufferers 6 months and older.

Watson Pharmaceuticals declared that its arm, Watson Laboratories, Inc., has inked a deal with Janssen Pharmaceuticals, Inc. on outstanding patent litigation linked to Watson's generic edition of Janssen's ORTHO TRI-CYCLEN® LO pills.

A novel report said that around 100- 200 million India’s residents might be carrying two deadly types of superbug, ha-MRSA and ca-MRSA – that are said to be resistant to all available antibiotic drugs.

Specialists as well as shareholders of pharmaceutical industry on February 08 called for setting up an autonomous drug regulatory authority (DRA) at federal level to govern, file and fix the costs of medications.

Dr Reddy’s Laboratories , the country's No. 2 drug manufacturer by sales, registered a forecast-hitting 88% increase in quarterly net profit as sales in its main U.S. market increased over two-folds.

Nirmal Bang has suggested ‘hold’ rating on Glenmark Pharma to attain a price target of Rs 364.

British drug manufacturer AstraZeneca declared that it has decided to slash costs by shutting its Quebec research and development plant, annihilating 132 jobs.

Poland's retail pharma market posted a drop of 24% year on year during the last month to PLN 1.4 billion in gross retail prices.

After two earlier rejections in 2010, Amylin Pharmaceutical’s diabetes medication Bydureon lastly bagged the Food and Drug Administration’s (FDA) nod on January 27.

Spectrum Pharmaceuticals has inked a deal to get hold of licensing rights to sell ZEVALIN (ibritumomab tiuxetan) jab for intravenous usage outside of the United States from Bayer Healthcare.

Fitch Ratings said that the 2012 viewpoint for the Indian pharmaceutical sector is static. The agency projects credit profiles to stay stable given that long-standing profits and profitability outlooks stay intact with moderate capital expenditure.

Relations between the administration and health experts dropped to a new low after Andrew Lansley charged them of contradicting his NHS reforms as they were disappoint about cuts to their salary as well as pensions.

RNA drug maker Alnylam Pharmaceuticals Inc. announced that it will slash around 33 percent of its jobs with the aim to diminish costs and concentrate on its most hopeful drug candidates

Innate Pharma SA (IPH), a French drug maker, grew up the most in over two months in Paris trading after the firm said a discovery released in the journal Science may give rise to novel infection fighting medications.

Cubist Pharmaceuticals stated that its fourth quarter profit declined by more than half owing to expenditures linked to its acquirement of constipation drug manufacturer Adolor Corp.

Drug manufacturer Novartis will slash around 1,960 jobs in US during 2012 in expectancy of lower sales for two of its high blood pressure medications.

Savient Pharmaceuticals has roped in David Veitch President of Savient Europe with effect from January 16, 2012.

Glenmark Pharmaceuticals projects sales of its speciality biz, which concentrates on branded products, to develop by about 20% in the Indian market by the
coming three years (2015).

Fleming Pharmaceuticals has sold four of its well known brands, comprising Ocean nasal spray, to a division of a Canadian drug firm.

Andrew Lansley has been forced to offer up an added £185 million boost to assist the NHS fund legal battles because of growing numbers of carelessness claims.

Pain pills such as Percocet and Opana from Endo Pharmaceuticals may be in short supply after their fabrication plant was closed for production as well as quality concerns.

Ariad Pharmaceuticals’s scrip had its “outperform” ranking reaffirmed by research forecasters at Rodman & Renshaw in a report released on January 14.

Amag Pharmaceuticals stated that it anticipates its fourth quarter earnings to miss Street expectations, though it repeated its full year financial 2012 viewpoint.

Swiss pharma giant Novartis stated that it was recalling four different medications sold over the counter in the US market following reports of a malfunction at one of its facilities.

Synta Pharmaceuticals is offering 7 million scrips of common stock to the public, with the prospective of making net income of $28.6 million, the company said.

Savient Pharmaceuticals declared that a product-specific billing system, or lasting J-code, for KRYSTEXXA® (pegloticase) became accessible on January 1, 2012.

Endo Pharmaceuticals has decided to pay around $180 million for licensing rights

Lupin Pharmaceuticals Ltd has bagged final authorization for its Fenofibrate Tabs, 48 mg and 145 mg potencies from
the USFDA.

Teva Pharmaceutical Industries Ltd stated that President and Chief Executive Shlomo Yanai would quit during May, after over 5 years at the helm.

Research based Indian pharma firms are ready to detain a key share of the US domestic market with growing number of filing of ANDAs.

Indian pharmaceutical firm, Zydus Cadila is eyeing to back out from its alliance with Eli Lilly, which involved combined drug detection for cardiovascular illnesses.